TRAF7-Mutated Fibromyxoid Spindle Cell Tumor of Bone: An Osseous Case Expanding the Spectrum of TRAF7-Mutated Tumors With Over 20 Years Clinical Follow-Up
Laura M. Warmke, Ani Toklu, Spencer M. Richardson, Christopher D. Collier, L. Daniel Wurtz, Lauren M. Ladd, Roman Shrestha, Devin J. Conway
{"title":"TRAF7-Mutated Fibromyxoid Spindle Cell Tumor of Bone: An Osseous Case Expanding the Spectrum of TRAF7-Mutated Tumors With Over 20 Years Clinical Follow-Up","authors":"Laura M. Warmke, Ani Toklu, Spencer M. Richardson, Christopher D. Collier, L. Daniel Wurtz, Lauren M. Ladd, Roman Shrestha, Devin J. Conway","doi":"10.1002/gcc.70118","DOIUrl":null,"url":null,"abstract":"<p><i>TRAF7</i> mutations are a rare occurrence in human cancer and have recently been described in a group of mesenchymal tumors with varying clinical course. Herein, we expand the spectrum of <i>TRAF7</i>-mutated fibromyxoid spindle cell tumors by reporting the first case to arise in bone. A 60-year-old woman presented with right knee pain and was incidentally found to have a left distal femur lesion, which was first detected 20 years prior when it was favored to be benign. Recent imaging studies revealed significant interval growth with focal cortical destruction and soft tissue extension. Histologic examination showed a bland spindle cell neoplasm with fibrous to myxoid stroma. Rare mitotic figures were present; necrosis and marked cytologic atypia were absent. Immunohistochemical work-up showed that the spindle cells only demonstrated focal cytoplasmic staining with L1CAM, and whole exome sequencing identified a <i>TRAF7</i> p.Y563C missense mutation. The tumor was resected, and the patient is recovering well at 2 months with no evidence of local recurrence or distant disease. This report is the first known case of a <i>TRAF7</i>-mutated fibromyxoid spindle cell tumor of bone with the longest clinical follow-up reported to date.</p>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"65 3","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12978061/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genes, Chromosomes & Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/gcc.70118","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
TRAF7 mutations are a rare occurrence in human cancer and have recently been described in a group of mesenchymal tumors with varying clinical course. Herein, we expand the spectrum of TRAF7-mutated fibromyxoid spindle cell tumors by reporting the first case to arise in bone. A 60-year-old woman presented with right knee pain and was incidentally found to have a left distal femur lesion, which was first detected 20 years prior when it was favored to be benign. Recent imaging studies revealed significant interval growth with focal cortical destruction and soft tissue extension. Histologic examination showed a bland spindle cell neoplasm with fibrous to myxoid stroma. Rare mitotic figures were present; necrosis and marked cytologic atypia were absent. Immunohistochemical work-up showed that the spindle cells only demonstrated focal cytoplasmic staining with L1CAM, and whole exome sequencing identified a TRAF7 p.Y563C missense mutation. The tumor was resected, and the patient is recovering well at 2 months with no evidence of local recurrence or distant disease. This report is the first known case of a TRAF7-mutated fibromyxoid spindle cell tumor of bone with the longest clinical follow-up reported to date.
期刊介绍:
Genes, Chromosomes & Cancer will offer rapid publication of original full-length research articles, perspectives, reviews and letters to the editors on genetic analysis as related to the study of neoplasia. The main scope of the journal is to communicate new insights into the etiology and/or pathogenesis of neoplasia, as well as molecular and cellular findings of relevance for the management of cancer patients. While preference will be given to research utilizing analytical and functional approaches, descriptive studies and case reports will also be welcomed when they offer insights regarding basic biological mechanisms or the clinical management of neoplastic disorders.